What is agtc?
Applied Genetic Technologies (agtc), founded in 1999 and based in Alachua, Florida, is a clinical-stage biotechnology firm. The company leverages its proprietary gene therapy platform to develop innovative treatments for patients suffering from severe diseases, with a particular focus on ophthalmology. Its core mission revolves around addressing unmet medical needs through advanced genetic interventions, positioning it as a key player in the development of next-generation therapeutics.
How much funding has agtc raised?
agtc has raised a total of $124.5M across 2 funding rounds:
Stock Offering
$50M
Stock Offering
$74.5M
Stock Issuance/Offering (2014): $50M, investors not publicly disclosed
Stock Issuance/Offering (2021): $74.5M, investors not publicly disclosed
What's next for agtc?
The recent major strategic investment signals a pivotal phase for agtc, likely enabling the acceleration of its product development pipeline and clinical trials. This capital infusion is expected to bolster its research and development efforts, potentially expanding its therapeutic reach beyond ophthalmology. The company's focus on gene therapy suggests a long-term strategy aimed at establishing durable treatments for genetic disorders, with future growth contingent on successful clinical outcomes and regulatory approvals.
See full agtc company page
